论文部分内容阅读
目的 回顾性研究头孢哌酮舒巴坦联合美罗培南治疗老年重症肺炎的临床疗效.方法选取2014 年2 月～2015 年2 月于我院就诊治疗的80 例老年重症肺炎患者临床资料, 所有患者随机分为对照组 (头孢哌酮舒巴坦治疗) 和研究组 (头孢哌酮舒巴坦联合美罗培南治疗), 比较两组患者临床疗效.结果 研究组治疗总有效率92.5% , 与同期对照组治疗总有效率80%相比较, 差异有统计学意义(P0.05);研究组治疗后TNF-α、 IL-1、 IL -6 水平均低于对照组, IL -10 水平高于对照组, 差异有统计学意义(P<0.05).结论 头孢哌酮舒巴坦联合美罗培南治疗老年重症肺炎效果优于头孢哌酮舒巴坦单用, 可作为临床治疗的优选方案加以推广使用.“,”Objective To investigate the efficacy of cefoperazone-sulbactam combined with meropenem in the treatment of elderly patients with severe pneumonia. Methods A total of 80 elderly patients with severe pneumonia in our hospital from February in 2014 to February in 2015 were recruited. The patients were randomly divided into the control group (cefoperazone-sulbactam ther-apy) and the experimental group (cefoperazone -sulbactam combined with meropenem therapy). The efficacy between two groups were compared. Results The overall efficacy rate was 92.5% in the experimental group and 80% in the control group. There was a significant difference between two groups (P0.05). The levels of TNF-α、 IL-1、 IL-6 in the experimental group were lower than those in the control group, while the level of IL-10 in the experimental group was higher (P<0.05). Conclusion Cefoperazone-sulbactam in combination with meropenem is more effective than meropenem alone in the treatment of elderly patients with severe pneumonia.